The whole debacle came to head with Tilray, a premium medical cannabis company, which was briefly worth $20 billion in September 2018, up as much as 94% in the span of a day. Some reports linked the sharp increase to the news that the Drug Enforcement Agency approved Tilray’s plan to import a cannabis product that could be used to treat neurological disorders.